巴西HIV阳性个体中药物代谢与转运基因多态性与依非韦伦不良反应的关联
在巴西里约热内卢一家医院的225例HIV阳性者中,89例有依非韦伦不良反应(43例为中枢神经系统不良反应),136例为对照。CYP2B6慢代谢基因型与依非韦伦不良反应风险升高相关。
要点
- CYP2B6 15582CC-516TT-983TT组合与全因不良反应风险升高相关(OR=7.26)。
- CYP2B6慢代谢组516TT或516GT-983CT与全因不良反应相关(OR=3.10)。
- CNS不良反应与CYP3A4 rs4646437的关联在校正多重比较后不再显著。
核心结论
- 在高度混血的巴西队列中,CYP2B6慢代谢基因型与依非韦伦不良反应风险升高相关。
研究设计与样本
- 研究纳入225例在巴西里约热内卢一家医院接受含依非韦伦方案治疗的HIV阳性个体,89例有依非韦伦不良反应(其中43例有中枢神经系统不良反应),136例为对照(至少治疗6个月后无任何抗逆转录病毒药物不良反应)。
- 选取ABCB1、CYP2A6、CYP2B6、CYP3A4、CYP3A5、NR1I2和NR1I3基因的67个候选多态性进行关联分析,并用28个祖先信息多态性评估混血程度。
- 关联分析采用校正性别和遗传祖先的logistic回归模型。
主要发现
- 队列中非洲、欧洲和美洲原住民混血程度广泛。
- 全因不良反应增加与CYP2B6基因型组合15582CC-516TT-983TT相关(OR=7.26,P=0.003)。
- 全因不良反应增加与CYP2B6慢代谢组516TT或516GT-983CT相关(OR=3.10,P=0.04)。
- 中枢神经系统不良反应与CYP3A4 rs4646437名义相关(OR=4.63,P=0.014),但校正多重比较后不显著。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: There are limited data regarding efavirenz pharmacogenetics in admixed populations. The Brazilian population is highly admixed. In a Brazilian cohort, we sought to characterize associations between efavirenz adverse effects (all-cause and CNS) and polymorphisms in seven genes known or suspected to affect efavirenz metabolism and transport. METHODS: We studied 225 HIV-positive individuals who had been prescribed efavirenz-containing regimens at a hospital in Rio de Janeiro, Brazil. Eighty-nine cases had efavirenz adverse effects, including 43 with CNS adverse effects, while 136 controls had no adverse effect of any antiretroviral after treatment for at least 6 months. A total of 67 candidate polymorphisms in ABCB1, CYP2A6, CYP2B6, CYP3A4, CYP3A5, NR1I2 and NR1I3 genes were selected for association analysis. Admixture was assessed using 28 ancestry-informative polymorphisms previously validated for the Brazilian population. Associations were evaluated with logistic regression models adjusted for sex and genetic ancestry. RESULTS: There was extensive African, European and Native American admixture in the cohort. Increased all-cause adverse effects were associated with the CYP2B6 genotype combination 15582CC-516TT-983TT (OR = 7.26, P = 0.003) and with the CYP2B6 slow metabolizer group 516TT or 516GT-983CT (OR = 3.10, P = 0.04). CNS adverse effects were nominally associated with CYP3A4 rs4646437 (OR = 4.63, P = 0.014), but not after adjusting for multiple comparisons. CONCLUSIONS: In a highly admixed Brazilian cohort, the CYP2B6 slow metabolizer genotype was associated with an increased risk of efavirenz adverse effects.
引用
- de Almeida TB, de Azevedo MCVM, Pinto JFDC, et al. Drug metabolism and transport gene polymorphisms and efavirenz adverse effects in Brazilian HIV-positive individuals. J Antimicrob Chemother. 2018. PMID: 29868865. doi:10.1093/jac/dky190
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。